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Liquisolid technology, as described by Spireas[1] may be 
used to transform a liquid into a free flowing, easily 
compressible and apparently dry powder by simple 
physical mixing with selected excipients named the 
carrier and coating material. The liquid portion can be a 
liquid drug, a drug suspension or a drug solution in 
suitable non-volatile liquid vehicles. This liquid is 
incorporated into the porous carrier material (Fig. 1). 
Organic solvent systems which are inert and preferably 
water-miscible with high boiling point, such as 
propylene glycol, liquid polyethylene glycols, or 
glycerine are best suitable as liquid vehicles. Upon 
saturation of the carrier with liquid, a liquid layer is 
formed on the particle surface which is readily adsorbed 
by the fine coating particles [2]. Hence, a dry, free 
flowing, and compressible powder is obtained. 
 
Fig. 1: Schematic representation of liquisolid systems
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Different excipients such as lubricants and disintegrants 
(immediate release) or matrix forming materials 
(sustained release) may be added to the liquisolid system 
to produce liquisolid compacts (Fig. 2).  
 
Fig. 2: Schematic outline of the steps involved in the 
preparation of liquisolid compacts [1] 
Liquisolid compacts of poorly soluble drugs containing a 
drug solution or drug suspension in a solubilising vehicle 
show enhanced drug release due to one or more of the 
following reasons, an increased surface area of drug 
available for release, an increased aqueous solubility of 
the drug, and an improved wettability of the drug 
particles [3-6]. Subsequently, this improved drug release 
may result in a higher drug absorption from the 
gastrointestinal tract and thus, an improvement in oral 
bioavailability[7, 8]. 
As shown in Fig. 3, drug release from liquisolid 
compacts is significantly faster than that from their 
directly compressed systems. Here, liquisolid compacts 
with hydrocortisone containing a 5 % [w/w] drug 
solution in polyethylene glycol 400 were investigated 
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using microcrystalline cellulose and colloidal silica as 
carrier and coating materials, respectively [9]. 
The liquisolid technology may also be used to prolong 
dissolution rate [1, 10-12]. Sustained release oral dosage 
forms are beneficial with regard to patient compliance 
because of the reduced dosing frequency. Ideally, a 
sustained release dosage form leads to therapeutic 
plasma levels, which are maintained throughout the 
dosing interval. It has been shown that with hydrophobic 
carriers such as Eudragit® RL and RS instead of 
hydrophilic carriers, sustained release systems may be 
obtained [13]. Sustained release from liquisolid compacts 
with the conventional carrier and coating materials may 
also be observed after addition of a matrix forming 
material such as hydroxypropyl methylcellulose [1]. 
 
Fig. 3:  Hydrocortisone release profiles from liquisolid 
compacts containing a 5 % [w/w] drug solution in 
polyethylene glycol 400 (●) and from directly 
compressed tablets (□) with the same drug dose of 10 mg 
[9] 
Liquisolid technology may be used to prepare sustained 
release tablets with a zero order drug release pattern (Fig. 
4). Here, liquisolid compacts with nifedipine containing 
a 30 % [w/w] drug suspension in polyethylene glycol 
400 were prepared using microcrystalline cellulose and 
colloidal silica as carrier and coating materials, 
respectively [1]. In addition, 22 % [w/w] of the matrix 
former hydroxypropyl methylcellulose with a viscosity 
grade of 15 mPa·s was added to obtain sustained drug 
release.  
 
Fig. 4:  Nifedipine release profiles from sustained release 
liquisolid compacts containing a 30 % [w/w] drug 
suspension in polyethylene glycol 400 () and from 
commercial tablets (●) (Procardia XL) with the same 
drug dose of 30 mg [1] 
LIQUISOLID SYSTEMS THEORY 
A powder can retain only certain amount of liquid while 
maintaining acceptable flow and compression properties. 
To calculate the required amounts of powder excipients 
(carrier and coating materials), a mathematical approach 
for the formulation of liquisolid systems has been 
developed by Spireas [1, 13]. This approach is based on the 
flowable (Ф-value) and compressible (Ψ-number) liquid 
retention potential introducing constants for each 
powder/liquid combination.   
The Ф-value of a powder represents the maximum 
amount of a given non-volatile liquid that can be retained 
inside its bulk [w/w] while maintaining an acceptable 
flowability. The flowability may be determined from the 
powder flow, by measurement of the angle of repose or 
by measurement of angle of slide[1]. 
The Ψ-number of a powder is defined as the maximum 
amount of liquid the powder can retain inside its bulk 
[w/w] while maintaining acceptable compactability 
resulting in compacts of sufficient hardness with no 
liquid leaking out during compression. The 
compactability may be determined by pactisity 
measurement[1] which describes the maximum (plateau) 
crushing strength of a one-gram tablet compacted at 
sufficiently high compression forces. 
The terms “acceptable flow and compression properties” 
imply the desired and thus preselected flow and 
compaction properties which must be met by the final 
liquisolid formulation. 
Depending on the excipient ratio (R) of the powder 
substrate an acceptably flowing and compressible 
liquisolid system can be obtained only if a maximum 
liquid load on the carrier material is not exceeded. This 
liquid/carrier ratio is termed “liquid load factor Lf“ [w/w] 
and is defined as the weight ratio of the liquid 
formulation (W) and the carrier material (Q) in the 
system:  
Lf =W /Q    Eq. (1) 
R represents the ratio between the weights of the carrier 
(Q) and the coating (q) material present in the 
formulation:  
R=Q/q       Eq. (2)  
The liquid load factor that ensures acceptable flowability 
(ΦLf ) can be determined by:  
ΦLf = Φ +φ⋅(1/R)     Eq. (3)  
where Φ and φ are the Ф-values of the carrier and 
coating material, respectively. Similarly, the liquid load 
factor for production of liquisolid systems with 
acceptable compactability (ΨLf ) can be determined by:  
ΨLf = Ψ +ψ⋅(1/R)     Eq. (4)  
where Ψ and ψ are the Ψ-numbers of the carrier and 
coating material, respectively.  
Therefore, the optimum liquid load factor (Lo) required 
to obtain acceptably flowing and compressible liquisolid 
systems is equal to either ΦLf or 
ΨLf , whichever 
represents the lower value. 
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As soon as the optimum liquid load factor is determined, 
the appropriate quantities of carrier (Qo) and coating (qo) 
material required to convert a given amount of liquid 
formulation (W) into an acceptably flowing and 
compressible liquisolid system may be calculated as 
follows:  
 
Qo =W /Lo    Eq. (5)  
and 
qo =Qo / R      Eq. (6)  
The validity and applicability of the above mentioned 
principles have been tested and verified by producing 




Liquisolid formulations for enhanced drug release 
 
Table 1: Formulations of liquisolid systems with enhanced/sustained drug release 
Polymer/ Variations Drug / Molecule Comments Reference 
Lactose + Cremophor® EL Griseofulvin Enhanced Dissolution was achieved 14 
Cremophor® EL, Synperonic® PE/L61, 
PEG400 + Avicel® PH102 
Naproxen Better shelf life 15 
Tween 80 + Microcrystalline Cellulose Piroxicam Enhanced Dissolution was achieved 6 
Avicel® PH102 Famotidine Enhanced Dissolution was achieved 16 
Neusilin® Griseofulvin Enhanced release was achieved 17 
Avicel®PH 200 Prednisolone Enhanced Dissolution was achieved 13 
Avicel PH 102, and Aerosil 200 Carbamazepine Enhanced Dissolution was achieved 18 
Silica–Eudragit RL or RS Theophylline 
Liquisolid compacts has a potential to 
produce zero-order release kinetics for 
less water soluble drugs 
19 
Eudragit RL or RS as the carrier and 
silica as the coating material 
Propranolol 
hydrochloride 
Sustained release was achieved 5 
Capryol™ 90,Solutol® HS-15 and 
Kollicoat® SR 30 D as non-volatile 
liquid vehicles 
Spironolactone Enhanced Dissolution was achieved 20 
Propylene glycol as solvent, Avicel 
PH102 as carrier, and Aerosil 200 as the 
coating material 
Valsartan Enhanced Dissolution was achieved 21 
PEG: polyethylene glycol 
Many poorly soluble drugs have been formulated as 
liquisolid systems showing enhanced drug release. 
Different liquid vehicles, carrier and coating materials 
were used to formulate these drug delivery systems 
(Table 1).   
MECHANISMS OF ENHANCED DRUG RELEASE 
FROM LIQUISOLID SYSTEMS  
Several mechanisms of enhanced drug release have been 
proposed in literature for liquisolid systems. The three 
main suggested mechanisms include an increased surface 
area of drug available for release, an increased aqueous 
solubility of the drug, and an improved wettability of the 
drug particles. Formation of a complex between the drug 
and excipients or any changes in crystallinity of the drug 
could be ruled out using DSC and XRPD measurements 
[4, 6]. 
a. Increased drug surface area  
When the drug within the liquisolid system is completely 
dissolved in the liquid vehicle, it is located in the powder 
substrate still in a solubilized, molecularly dispersed 
state. Hence, the available surface area for drug release is 
much higher than that of drug particles within directly 
compressed tablets. 
Similarly, when drug content exceeds the solubility limit, 
fraction of undissolved drug in the liquid vehicle 
increases and the release rate decreases. With various 
drugs it could be observed that the release rates are 
directly proportional to the fraction of the drug 
molecularly dispersed (FM) in the liquid formulation 
[3, 5, 
11, 14]. FM is defined by Spireas as the ratio between the 
drug's solubility (Sd) in the liquid vehicle and the actual 
drug concentration (Cd) in this vehicle carried by each 
system [9]. 
Therefore:  
FM =Sd /Cd    Eq. (7)  
where FM =1 if Sd ≥Cd .  
Fig. 5 shows the effect of the fraction of the molecularly 
dispersed drug (FM) on the release rate of hydrocortisone 
formulated as liquisolid compacts containing various 
drug concentrations in varying amounts of propylene 
glycol as liquid vehicle. The drug release rate increases 
linearly with increasing FM. However, this linear increase 
may be observed only above a certain FM-limit.   
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Fig. 5: Effect of the fraction of molecularly dispersed 
drug (FM) on the hydrocortisone release rate at 30 min of 
liquisolid compacts (means ± SD , n = 3) [9] 
b. Increased aqueous solubility of the drug  
In addition to the first mechanism of drug release 
enhancement it is expected that Cs, the solubility of the 
drug, might be increased with liquisolid systems. In fact, 
the relatively small amount of liquid vehicle in a 
liquisolid compact is not sufficient to increase the overall 
solubility of the drug in the aqueous dissolution medium. 
However, at the solid/liquid interface between an 
individual liquisolid primary particle and the release 
medium it is possible that in this microenvironment the 
amount of liquid vehicle diffusing out of a single 
liquisolid particle together with the drug molecules might 
be sufficient to increase the aqueous solubility of the 
drug if the liquid vehicle acts as a cosolvent. The overall 
increase in the solubility of drugs caused by liquisolid 
systems was confirmed by Yadav et al.[22]. 
c. Improved wetting properties  
Due to the fact that the liquid vehicle can either act as 
surface active agent or has a low surface tension, wetting 
of the liquisolid primary particles is improved. Improved 
wettability in-turn results into improved dissolution of 
drug. Wettability of these systems has been demonstrated 
by measurement of contact angles [6] and water rising 
times[22].  
OPTIMIZATION OF LIQUISOLID 
FORMULATIONS WITH ENHANCED DRUG 
RELEASE 
The liquisolid technology has been successfully applied 
to low dose, poorly water soluble drugs. The formulation 
of a high dose, poorly soluble drug is one of the 
limitations of the liquisolid technology. As the release 
rates are directly proportional to the fraction of 
molecularly dispersed drug (FM) in the liquid 
formulation, a higher drug dose requires higher liquid 
amounts for a desired release profile. Also, to obtain 
liquisolid systems with acceptable flowability and 
compactability high levels of carrier and coating 
materials are needed. However, this results in an increase 
in tablet weight ultimately leading to tablet sizes which 
are difficult to swallow. Therefore, to overcome this and 
various other problems of the liquisolid technology 
several formulation parameters may be optimized (Table 
2).  
In various studies the effect of different types of non-
volatile liquid vehicles has been investigated. The results 
suggest that the selection of a liquid vehicle with a high 
solubilizing capacity for the drug and thus, an increased 
FM, leads to enhanced release profiles [23]. That means 
that by selection of a liquid vehicle with optimum 
solubilizing properties the amount of liquid and thus, the 
weight and size of the liquisolid compacts can be 
reduced. However, in addition to the drug solubility in 
the liquid vehicle other physicochemical characteristics 
of the liquid vehicles such as polarity, viscosity, 
molecular weight, chemical structure, and lipophilicity 
may also have an effect on drug release [24]. 
A further approach to minimize tablet weight is to 
increase the liquid load factor by using carrier and 
coating materials with a high specific surface area or by 
adding PVP to the liquid formulation. It was found that 
the higher the specific surface area of an excipient the 
higher the liquid load factor [2]. For instance, the liquid 
adsorption capacity of microcrystalline cellulose (1.18 
m²/g) is higher than that of lactose (0.35 m²/g), starch 
(0.6 m²/g), and sorbitol (0.37 m²/g) [4]. Fujicalin® (30 
m²/g), a spherically granulated dicalcium phosphate 
anhydrous, and Neusilin® US2 (300 m²/g), a magnesium 
aluminometasilicate, turned out to be very effective 
excipients for liquid adsorption while maintaining 
acceptable flow and compaction properties [25].
 
Table 2: Optimization of formulation parameters for liquisolid systems with immediate drug release 
Formulation parameter Optimization Effect 
liquid vehicle 
high drug solubility in the 
vehicle 
increased fraction of the molecularlydispersed drug 
(FM) 
carrier and coating materials high specific surfacearea increased liquid load factor (Lf) 
addition of excipients 
Polyvinylpyrrolidone(PVP) 
increased liquid load factor (Lf), increased viscosity of 
liquid vehicle,inhibition of precipitation 
Superdisintegrant fast disintegration 
excipient ratio (R) high R-value fast disintegration, inhibition of precipitation 
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Khaled [8] noticed precipitation and consequently 
retention of the drug in the cavities of porous excipients 
upon contact of the liquid formulation with the release 
medium. This retention could be minimized by using 
either a diluted drug solution or PVP as crystallization 
inhibitor. Moreover, PVP may also act as binder during 
compaction leading to an increase of the liquid load 
factor [1].  
The release rate of a drug from a dosage form is 
dependent on its disintegration and the dissolution rate of 
the drug. Therefore, it is very important for liquisolid 
systems with enhanced drug release to ensure that 
disintegration is not the rate-limiting step and drug 
dissolution is not hindered by a slow disintegration of the 
dosage form. It was found that the release rate increases 
by addition of superdisintegrants such as sodium starch 
glycolate or croscarmellose sodium to the liquisolid 
formulation[22].  
Another formulation parameter that may be optimized is 
the ratio of carrier to coating material (R). An increase in 
the R-value results in an enhanced release rate if 
microcrystalline cellulose and colloidal silica are used as 
carrier and coating materials, respectively. Liquisolid 
compacts with high R-values contain high amounts of 
microcrystalline cellulose, low quantities of colloidal 
silica, and low liquid/powder ratios. This is associated 
with enhanced wicking, disintegration and thus, 
enhanced drug release. In contrast, if high amounts of 
colloidal silica are used, which means that the R-value is 
low, the liquisolid compact is overloaded with liquid 
formulation due to a high liquid load factor. In such 
cases, even though drug diffusion out of the primary 
particles may be rapid, oversaturation might occur 
resulting in local precipitation/ recrystallization of the 
drug and thus decreased release rates. Moreover, as 
colloidal silica is a hydrophobic material high amounts 
of it can cause retardation of drug release. Therefore, 
Spireas et al. recommend a minimum R-value of 20[13]. 
In the case of liquisolid sustained release compacts lower 
R-values may be used. 
Stability of liquisolid systems with enhanced drug 
release  
To obtain information on the stability of liquisolid 
systems, the effects of storage on the release profile and 
the crushing strength of liquisolid compacts were 
investigated. Stability studies of liquisolid systems 
containing polythiazide (40 °C/ 42 and 75 % R.H., 12 
weeks), hydrocortisone (ambient conditions, 10 months) 
[1], carbamazepine (25 °C/ 75 % R.H., 6 months), 
indomethacin (25 °C/ 75 % R.H., 12 months), piroxicam 
(25 °C/ 75 % R.H., 6 and 9 months, respectively), or 
naproxen (20 °C/ 76 % R.H., 4 weeks) showed that 
storage at different conditions neither had an effect on 
the hardness nor on the release profiles of liquisolid 
compacts. This indicates that the technology is a 
promising technique to enhance the release rate without 
having any physical stability issues. 
LIQUISOLID FORMULATIONS FOR SUSTAINED 
DRUG RELEASE  
Numerous methods have been described to produce 
sustained release formulations, among which the 
liquisolid technology is a quite new and promising 
technology resulting in a sustained release pattern with 
zero order kinetics [8, 12]. So far, only few drugs have been 
formulated as liquisolid systems with prolonged drug 
release. In Table 3 the formulations of these drugs with 
the respective liquid vehicle, carrier and coating material 
as well as the additional retarding agent (matrix forming 
material) are listed. 
 
Table 3: Formulations of liquisolid systems with sustained drug release 
Drug Liquid vehicle Carrier & coating material Additional retardant agent Ref. 
Nifedipine PEG 400 MCC & ColloidalSilica HPMC(15 mPa·s) 1, 26 
Propranolol HCl Polysorbate 80 Eudragit® RS or RL &Colloidal Silica HPMC (4000 mPa·s) 5, 27 
Theophylline Polysorbate 80 Eudragit® RS or RL &Colloidal Silica HPMC (4000 mPa·s) 28 
Tramadol HCl PG MCC & ColloidalSilica HPMC(4000 mPa·s) 29 
 
PEG: polyethylene glycol, PG: propylene glycol, MCC: 
microcrystalline cellulose, HCl: hydrochloride, HPMC: 
hydroxypropyl methylcellulose 
Mechanisms of sustained drug release from liquisolid 
systems  
With X-ray crystallography and DSC measurements it 
could be confirmed, that sustained drug release from 
these liquisolid compacts is not caused by a change in 
crystallinity or by complex formation of the drug during 
the manufacturing process of the sustained release 
liquisolid formulations [27]. Liquisolid formulations with 
sustained drug release may contain hydrophobic carriers 
such as Eudragit® RL or RS instead of hydrophilic 
carriers, the latter being used for fast release liquisolid 
formulations [5]. Hydrophobic carriers may lead to poor 
wetting properties of the compacts resulting in slow 
disintegration and thus, prolonged drug release. 
Accordingly, the liquid vehicle may affect drug release. 
A comparison of drug release from conventional matrix 
tablets (direct compression) and liquisolid compacts, 
both containing Eudragit® RS or RL as matrix forming 
material, showed that the retardation effect of liquisolid 
compacts with polysorbate 80 as liquid vehicle is much 
more higher than that of conventional matrix tablets [5]. 
This confirms the important role of the liquid vehicle in 
sustaining drug release from liquisolid matrix systems. It 
was shown that the liquid vehicle polysorbate 80 may act 
as a plasticizer [30] and thus, decreases the glass transition 
temperature of the polymer Eudragit® RS. Similarly, 
with liquisolid compacts the coalescence of the polymer 
particles occurs at lower temperatures than with 
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conventional matrix tablets. This more pronounced 
coalescence of polymer particles of liquisolid compacts 
leads to a matrix with lower porosity and higher 
tortuosity. Consequently, the drug is surrounded by a 
fine network of the hydrophobic polymer resulting in a 
sustained release of the drug [31].  
Moreover, it has been shown that the addition of 
hydroxypropyl methylcellulose (HPMC) increases the 
retardation effect of liquisolid compacts[1]. HPMC is 
commonly used for the preparation of hydrophilic matrix 
systems. Depending on its molecular weight the polymer 
either swells in contact with water and forms a hydrated 
matrix layer through which the drug has to diffuse or 
erodes resulting in a zero order drug release kinetic [43]. 
In the case of HPMC it was also found that a stronger 
retardation effect was observed with liquisolid compacts 
as compared to directly compressed tablets (conventional 
formulation) [38]. 
Optimization of liquisolid formulations with 
sustained drug release  
In contrast to liquisolid compacts with immediate drug 
release liquisolid sustained release formulations may be 
optimized by selection of low R-values, suspensions with 
a high percentage of undissolved drug and by avoidance 
of disintegrants.   
If the R-value is low, which means that the applied 
amount of silica is high, the liquisolid compacts are 
overloaded with liquid formulation due to a high liquid 
load factor. In such cases oversaturation might occur 
resulting in local precipitation of the drug and thus, 
decreased release rates [18, 29]. Moreover, the higher the 
percentages of undissolved drug in the liquid formulation 
the slower the release rate. This is especially important 
for poorly soluble drugs, as the dissolution rate of these 
drugs is low. In addition, as drug release from a tablet is 
dependent on the disintegration of the tablet and the 
subsequent dissolution of the drug, the absence of 
disintegrants, which prevents disintegration, will slow 
down drug release.  
Furthermore, it was shown with liquisolid compacts that 
the higher the HPMC concentration and the higher the 
amount of Eudragit® RS / RL, respectively, the more 
pronounced the decrease in drug release [31]. 
CONCLUSION 
Various methods are known to improve water solubility 
and drug release, among which the liquisolid technology 
is one of the most promising approaches. With this 
technology liquids such as solutions or suspensions of 
poorly soluble drugs in a non-volatile liquid vehicle are 
converted into acceptably flowing and compressible 
powders by simple physical blending with selected 
excipients named the carrier and the coating material. As 
highest drug release rates are observed with liquisolid 
compacts containing a drug solution as liquid portion, 
liquisolid compacts may be optimized by selection of the 
liquid vehicle and the carrier and coating materials. The 
addition of disintegrants may further accelerate drug 
release from liquisolid compacts. The liquisolid 
technology may also be used for the preparation of 
sustained release formulations with zero order release 
pattern. Thus, a constant plasma level will be reached, 
which is maintained throughout the dosing interval. For 
sustained release liquisolid compacts, the selection and 
the concentration of the excipients such as liquid vehicle, 
retarding agent (matrix forming material) as well as 
carrier and coating material play an important role. The 
liquisolid approach is a promising technology because of 
the simple manufacturing process, low production costs 
and the possibility of industrial manufacture due to the 




1. Spiridon Spireas, E.F.R.N.P.A., Liquisolid systems and 
methods of preparing same. 2002: US. 
2. Spireas S.S., C.I. Jarowski, and B.D. Rohera, Powdered 
solution technology: principles and mechanism. 
Pharmaceutical research, 1992. 9(10): p. 1351-1358. 
3. Javadzadeh Y., et al., Evaluating retardation and 
physicochemical properties of co-ground mixture of Na- 
diclofenac with magnesium stearate. Powder Technology, 
2012. 218(0): p. 51-56. 
4. Javadzadeh Y., B. Jafari-Navimipour, and A. Nokhodchi, 
Liquisolid technique for dissolution rate enhancement of a high 
dose water-insoluble drug (carbamazepine). Int J Pharm, 2007. 
341(1-2): p. 26-34. 
5. Javadzadeh Y., L. Musaalrezaei, and A. Nokhodchi, Liquisolid 
technique as a new approach to sustain propranolol 
hydrochloride release from tablet matrices. Int J Pharm, 2008. 
362(1-2): p. 102-8. 
6. Javadzadeh Y., et al., Enhancement of dissolution rate of 
piroxicam using liquisolid compacts. Farmaco, 2005. 60(4): p. 
361-5. 
7. El-Houssieny B.M., L. Wahman, and N. Arafa, Bioavailability 
and biological activity of liquisolid compact formula of 
repaglinide and its effect on glucose tolerance in rabbits. 
Bioscience trends, 2010. 4(1). 
8. Khaled K.A., Y.A. Asiri, and Y.M. El-Sayed, In vivo 
evaluation of hydrochlorothiazide liquisolid tablets in beagle 
dogs. International journal of pharmaceutics, 2001. 222(1): p. 
1-6. 
9. Spireas S., S. Sadu, and R. Grover, In vitro release evaluation 
of hydrocortisone liquisolid tablets. Journal of pharmaceutical 
sciences, 1998. 87(7): p. 867-872. 
10. Nokhodchi A., C.M. Hentzschel, and C.S. Leopold, Drug 
release from liquisolid systems: speed it up, slow it down.  
Expert opinion on drug delivery, 2011. 8(2): p. 191-205. 
11. Karmarkar A.B., I.D. Gonjari, and A.H. Hosmani, Liquisolid 
technology for dissolution rate enhancement or sustained 
release. Expert opinion on drug delivery, 2010. 7(10): p. 1227-
1234. 
12. Spireas S. and S. Bolton. Sustained-release liquisolid 
compacts. in Proc Int Symp Control Rel Bioact Mater. 1998. 
13. Spireas, S., Enhancement of prednisolone dissolution 
properties using liquisolid compacts. International Journal of 
Pharmaceutics, 1998. 166(2): p. 177-188. 
14. Elkordy A.A., et al., Combination of lactose (as a carrier) with 
Cremophor® EL (as a liquid vehicle) to enhance dissolution of 
griseofulvin. Powder Technology, 2013. 246(0): p. 182-186. 
15. Tiong, N. and A.A. Elkordy, Effects of liquisolid formulations 
on dissolution of naproxen. Eur J Pharm Biopharm, 2009. 
73(3): p. 373-84. 
16. Fahmy R.H. and M.A. Kassem, Enhancement of famotidine 
dissolution rate through liquisolid tablets formulation: in vitro 
and in vivo evaluation. Eur J Pharm Biopharm, 2008. 69(3): p. 
993-1003. 
17. Hentzschel C.M., et al., Enhancement of griseofulvin release 
from liquisolid compacts. Eur J Pharm Biopharm, 2012. 80(1): 
p. 130-5. 
Kala et al                                  Journal of Drug Delivery & Therapeutics; 2014, 4(3), 25-31 31 
© 2011-14, JDDT. All Rights Reserved                                        ISSN: 2250-1177                                     CODEN (USA): JDDTAO 
18. Tayel S.A., Soliman, II, and D. Louis, Improvement of 
dissolution properties of Carbamazepine through application 
of the liquisolid tablet technique. Eur J Pharm Biopharm, 2008. 
69(1): p. 342-7. 
19. Nokhodchi A., et al., Liquisolid compacts: the effect of 
cosolvent and HPMC on theophylline release. Colloids Surf B 
Biointerfaces, 2010. 79(1): p. 262-9. 
20. Elkordy A.A., X.N. Tan, and E.A. Essa, Spironolactone 
release from liquisolid formulations prepared with Capryol 90, 
Solutol(R) HS-15 and Kollicoat(R) SR 30 D as non-volatile 
liquid vehicles. Eur J Pharm Biopharm, 2012. 83(2): p. 203-
223. 
21. Chella N., N. Shastri, and R.R. Tadikonda, Use of the liquisolid 
compact technique for improvement of the dissolution rate of 
valsartan. Acta Pharmaceutica Sinica B, 2012. 2(5): p. 502-
508. 
22. Yadav V. and A. Yadav, Improvement of Solubility and 
Dissolution of Indomethacin by Liquisolid and Compaction 
Granulation Technique. Journal of Pharmaceutical Sciences & 
Research, 2009. 1(3). 
23. Nokhodchi A., et al., The effect of type and concentration of 
vehicles on the dissolution rate of a poorly soluble drug 
(indomethacin) from liquisolid compacts. J Pharm Pharm Sci, 
2005. 8(1): p. 18-25. 
24. Grover R., S. Spireas, and C. Lau-Cam, Development of a 
simple spectrophotometric method for propylene glycol 
detection in tablets. J Pharm Biomed Anal, 1998. 16(6): p. 
931-8. 
25. Hentzschel C.M., A. Sakmann, and C.S. Leopold, Suitability of 
various excipients as carrier and coating materials for 
liquisolid compacts. Drug development and industrial 
pharmacy, 2011. 37(10): p. 1200-1207. 
26. Gubbi S. and R. Jarag, Liquisolid technique for enhancement of 
dissolution properties of Bromhexine Hydrochloride. Research 
Journal of Pharmacy and Technology, 2009. 2(2): p. 382-386. 
27. Nokhodchi A., Y. Javadzadeh, and L. Mosaalrezaei, Liquisolid 
technique for sustaining the drug release from compacts.  
Journal of Pharmacy and Pharmacology, 2007. 59: p. 49. 
28. Nokhodchi A., et al., Liquisolid compacts: The effect of 
cosolvent and HPMC on theophylline release. Colloids and 
Surfaces B: Biointerfaces, 2010. 79(1): p. 262-269. 
29. Gonjari I.D., A.B. Karmarkar, and A.H. Hosmani, Evaluation 
of in vitro dissolution profile comparison methods of sustained 
release tramadol hydrochloride liquisolid compact 
formulations with marketed sustained release tablets. Digest 
Journal of Nanomaterials & Biostructures (DJNB), 2009. 4(4). 
30. Gruetzmann R. and K.G. Wagner, Quantification of the 
leaching of triethyl citrate/polysorbate 80 mixtures from 
Eudragit® RS films by differential scanning calorimetry. 
European journal of pharmaceutics and biopharmaceutics, 
2005. 60(1): p. 159-162. 
31. Azarmi S., W. Roa, and R. Lobenberg, Current perspectives in 
dissolution testing of conventional and novel dosage forms. Int 
J Pharm, 2007. 328(1): p. 12-21. 
 
 
 
